Education
About Us
Working with TipRanks
Follow Us
InnoCan Pharma (TSE:INNO)
:INNO
Total Valuation
InnoCan Pharma has a market cap or net worth of C$33.74M. The enterprise value is C$0.00.
Market CapC$33.74M
Enterprise ValueC$0.00
Share Statistics
InnoCan Pharma has 4,498,772 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding4,498,772
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
InnoCan Pharma’s return on equity (ROE) is -0.35 and return on invested capital (ROIC) is 5.06%.
Return on Equity (ROE)-0.35
Return on Assets (ROA)-0.20
Return on Invested Capital (ROIC)5.06%
Return on Capital Employed (ROCE)-0.18
Revenue Per Employee2.68M
Profits Per Employee-23.82K
Employee Count11
Asset Turnover3.18
Inventory Turnover0.98
Valuation Ratios
The current PE Ratio of InnoCan Pharma is ―. InnoCan Pharma’s PEG ratio is 0.34.
PE Ratio―
PS Ratio1.35
PB Ratio7.71
Price to Fair Value7.71
Price to FCF-25.00
Price to Operating Cash Flow-52.62
PEG Ratio0.34
Income Statement
In the last 12 months, InnoCan Pharma had revenue of 29.44M and earned -1.83M in profits. Earnings per share was -0.42.
Revenue29.44M
Gross Profit26.19M
Operating Income-1.25M
Pretax Income919.00K
Net Income-1.83M
EBITDA961.00K
Earnings Per Share (EPS)-0.42
Cash Flow
In the last 12 months, operating cash flow was 572.00K and capital expenditures -14.00K, giving a free cash flow of 558.00K billion.
Operating Cash Flow572.00K
Free Cash Flow558.00K
Free Cash Flow per Share0.12
Dividends & Yields
InnoCan Pharma pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-0.02
52-Week Price Change-40.82%
50-Day Moving Average13.67
200-Day Moving Average13.20
Relative Strength Index (RSI)21.10
Average Volume (3m)920.00
Important Dates
InnoCan Pharma upcoming earnings date is Mar 26, 2026, Before Open (Confirmed).
Last Earnings DateNov 26, 2025
Next Earnings DateMar 26, 2026
Ex-Dividend Date―
Financial Position
InnoCan Pharma as a current ratio of 4.09, with Debt / Equity ratio of 33.21%
Current Ratio4.09
Quick Ratio2.61
Debt to Market Cap0.00
Net Debt to EBITDA-5.20
Interest Coverage Ratio-178.14
Taxes
In the past 12 months, InnoCan Pharma has paid 1.18M in taxes.
Income Tax1.18M
Effective Tax Rate1.29
Enterprise Valuation
InnoCan Pharma EV to EBITDA ratio is 36.26, with an EV/FCF ratio of -21.86.
EV to Sales1.18
EV to EBITDA36.26
EV to Free Cash Flow-21.86
EV to Operating Cash Flow-22.07
Balance Sheet
InnoCan Pharma has C$10.22M in cash and marketable securities with C$2.12M in debt, giving a net cash position of C$8.10M billion.
Cash & Marketable SecuritiesC$10.22M
Total DebtC$2.12M
Net CashC$8.10M
Net Cash Per ShareC$1.80
Tangible Book Value Per ShareC$1.67
Margins
Gross margin is 88.45%, with operating margin of -4.24%, and net profit margin of -6.23%.
Gross Margin88.45%
Operating Margin-4.24%
Pretax Margin3.12%
Net Profit Margin-6.23%
EBITDA Margin3.26%
EBIT Margin3.15%
Analyst Forecast
The average price target for InnoCan Pharma is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast-3.94%
EPS Growth Forecast-17.62%